VKTX has been in the news 450% more than usual
Aug 19, 2025, 2:32 PM
-10.71%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
VKTX has been in the news recently: Eli Lilly and Co. has issued a 40-year bond, leading to speculation that Viking Therapeutics Inc. could be a potential acquisition target. Meanwhile, Viking Therapeutics recently reported disappointing Phase 2 trial results for its obesity drug VK2735, causing its shares to drop over 30%.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.